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ABSTRACT 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by 
symmetric joint inflammation that often involves the small joints of the hands and feet, with 
progressive destruction, deformity, and disability of the joints. Small joints of the hands and 
feet are frequently the first to be involved in RA, which is why methods for assessment of 
these joints are of particular importance at the onset of RA and early stage of the disease. The 
results of this thesis have highlighted the role of conventional radiography, Digital X-ray 
radiogrammetry (DXR) and musculoskeletal ultrasound (MSUS) in the diagnosis and 
management of RA.  
Paper I is based on the study about clinical and radiographic outcomes in patients with early 
RA who responded well to initial Methotrexate (MTX) monotherapy. Most early RA patients 
who achieved low disease activity after 3–4 months of MTX monotherapy continued to have 
low disease activity during 2 years follow-up. However, marked radiographic progression 
occurred in a proportion of patients, even despite sustained DAS28 remission.  
Paper II aimed to evaluate whether a significant decrease of cortical bone mineral density 
(BMD) measured by DXR during the first year of RA correlated with radiographic 
progression after 2 years. The results indicated that patients with significant decrease of 
DXR-BMD had significantly greater risk for radiographic progression, compared with 
patients without. Evaluation of RA patients with significant decrease in DXR-BMD during 
the first year of the disease helps to identify patients with higher risk for radiographic 
progression later in the disease course. However, future studies should investigate whether 
decrease in DXR-BMD during the first 3 or 6 months of the disease could indicate the same 
results. 
Paper III is based on a study about clinical predictors at the time of RA diagnosis for rapid 
radiographic progression (increase > 5 units according to the Sharp score modified by van der 
Heijde after one year). The results from paper III indicated that baseline erosions, level of 
acute phase reactant and current smoking status were independent predictors for radiographic 
progression after 1 year. These results remained after further adjustment for treatment 
strategy. Three dimensional risk matrix including current smoking status, erosions and C-
reactive protein showed a 12–63% risk gradient from patients carrying none compared with 
all predictors. 
Paper IV aimed to assess the utility of MSUS in patients with suspected inflammatory 
arthritis, using a probabilistic approach. In this study, the proportion of patients with 
  
 
maximal diagnostic certainty for inflammatory arthritis was increased significantly after 
performing MSUS. The similar significant increase was also observed for diagnostic 
certainty of RA. The findings from MSUS agreed with the final diagnosis in more than 
95% of patients.  
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1 INTRODUCTION 
 
1.1 CHRONIC ARTHRITIS 
The word arthritis is derived from the Greek words for joint (arthrein) and inflammation (it 
is). The classic signs for arthritis are pain (dolor), heat (calor), swelling (tumor), redness 
(rubor) and decreased function (functio laesa). The joint inflammation is considered chronic 
if it lasts more than six weeks. In chronic arthritis, the anatomy of synovium undergoes 
changes including an increase in the number of lining cells, hyperplasia of the lining layer 
and hyperemia [1, 2]. This remodeling of synovial tissue results in the formation of “pannus” 
which is a continuous mass of synovial cells spreading out over and invading cartilage and 
subchondral bone [3, 4] leading to the destruction of joints. 
 
1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is one of the most common systemic inflammatory disorders and 
affects 0.5-1 % of the general population [5]. The female/male ratio is about 2.5:1. The 
disease can occur at any age but it is most common between 40 and 70 years. The disease 
onset is mostly insidious and it sometimes takes several months before a confirmed diagnosis 
can be made [6]. The main symptoms of the disease are pain, stiffness and swelling of 
peripheral joints but other organs such as the lungs and blood vessels as well as the 
hematopoietic system can also be involved [7]. Synovial inflammation and aggressive tissue 
front called pannus invades and destroys articular structure locally [3]. Joint destruction 
because of synovitis can occur early and a proportion of patients develop bone erosion during 
the first 2 years of the disease [8].  
 
1.2.1 Pathogenesis 
The first concept of immune-reactivity of RA was the identification of rheumatoid factor  
(RF) that was observed first by Waaler in 1939 and later by Rose in 1948 [9]. The presence of 
RF predicts more aggressive and destructive course [3]. The primary potential pathogenesis 
of RF seems to be as an initiator of immune-complex mediation [10]. Complement fixation 
by immune-complex containing RF and other auto antibodies releases chemotactic mediators 
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such as C5a leading to the recruitment of inflammatory cells such as neutrophils to the 
inflammatory joints. T-cells are the dominant lymphocytes that infiltrate the rheumatoid 
synovium and CD4+ cells (Th2) predominate over CD8+ cells (Th1) in most of RA patients, 
leading to disturbed balance between T-cell derived cytokines. Other type of T-cells, such as 
Th17 cells can also play a critical role in pathogenesis of RA. The most important risk factor 
for RA is the presence of HLA-class II and particularly HLA-DRB 1 [11] and this 
observation lead to the shared epitope hypothesis several decades ago. According to this 
hypothesis, presence of a specific amino acid sequence in the protein molecule of DRB 1 (the 
shared epitope) facilitates presentation of athritogenic peptides to T-cells [12]. Huizinga et al 
in 2005 showed that the share epitope (SE) alleles are only a risk factor for RA patients who 
are positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies [13]. Anti-CCP 
antibodies are highly specific for RA and can be detected years before the first clinical 
manifestation of the disease [14]. Van der Helm et al later showed that the share epitope 
alleles were directly associated with the presence of anti-CCP antibodies and moreover 
correlated to the level of anti-CCP antibodies in RA patients [15]. None of the genetic risk 
factors by themselves is sufficient enough to cause rheumatoid arthritis. The most prominent 
gene-environment interaction in RA pathogenesis is smoking and several years of smoking 
seems to increase the risk for development of RA. The combination of HLA-DRB1 SE and 
smoking is a risk factor for anti-CCP positive RA but not anti-CCP negative RA [16]. 
  
1.2.2 Clinical features and diagnosis 
The course of RA can vary extremely. Some patients may have very acute and severe disease 
onset with polyarthritis, fever and extra-articular manifestation whereas the insidious onset of 
the symptoms is most common. Joint symptoms include pain, stiffness and swelling whereas 
concomitant tenosynovitis and bursitis may be present from the beginning. Generalized 
symptoms such as low fever, weakness and weight loss might also be present. There is no 
pathognomonic symptom or sign for diagnosis. The American College of Rheumatology 
(ACR) classification criteria from 1987, table 1, [17] was designed to help rheumatologists to 
differentiate RA from other inflammatory arthritides. These criteria were originally created 
for research rather than diagnosis and the sensitivity of the ACR criteria is low during early 
stages of the disease [18]. Due to importance of and need for early diagnosis allowing early 
aggressive treatment [19] new classification criteria were created by ACR and European 
League against Rheumatism (EULAR) [20], table 2.   
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TABLE 1: ACR criteria for rheumatoid arthritis [17]  
 
TABLE 2: The 2010 EULAR/ACR classification criteria for rheumatoid arthritis [20] 
At least four of the following criteria:
1- Morning stiffness > 1 hour
2-Arthritis of at least 3 joints area
3-Arthritis of the hands joints
4- Symmetric arthritis
5- Rheumatoid nodules
6- Presence of rheumatoid factor
7- radiographic changes
Criteria 1-4 must have been present for > 6 weeks
Target population
1- have at least one joint with definite clinical synovitis
2- with synovitis not better explained by another disease 
A score of  at least 6/10 is needed for classification of a patient  as having  definite RA
a- Joint involvement Score
1 large joint 0
2-10 large joints 1
1-3 small joints (with or without involvement of large joints) 2
4-10 small joints  (with or without involvement of large joints) 3
> 10 joints (at least 1 small joint) 5
b- Serology (at least one test result is needed)
Negative RF and negative ACPA 0
Low positive RF or low positive ACPA 1
High positive RF or high positive ACPA 2
c- Acute phase reactants (at least one test result is needed)
Normal CRP and normal ESR 0
Abnormal CRP or abnormal ESR 1
d- Duration of symptoms
< 6 weeks 0
> 6 weeks 1
 4 
 
The disease characteristic is recurrent inflammation of almost any synovial joint and typically 
small joints of the hands and feet. The chronic inflammation leads to different degrees of 
joint destruction and some radiographic changes occurs during the first years of the disease 
despite conventional treatment and low disease activity [21, 22]. 
 
1.2.3 Treatment  
1.2.3.1 Disease Modifying Anti Rheumatic Drugs (DMARDs) 
Initiating treatment with DMARDs in patients with early RA is recommended if there is no 
contraindication [23]. The most common used DMARDs are Methotrexate, Sulfasalazine, 
Leflunomide, Cyclosporin A and Hydroxychlroquine. The characteristics of the these 
agents are slow onset of action, improved symptoms and signs of arthritis, improved 
functional status, protection against radiographic destruction in the bone and cartilage and 
improved acute phase response [24, 25].  Methotrexate (MTX) is the most frequently used 
DMARD in RA. MTX in high dosage blocks purine synthesis and has a cytotoxic effect. 
However at the low dosage which is used in RA, generalized cytotoxicity does not occur. 
MTX suppresses disease activity [26] and has a protective effect against joint destruction 
[27]. The common dosage used in RA patients is between 15 and 25 mg weekly. Folic acid 
supplement should be added in order to reduce liver toxicity. Many previous studies 
showed that RA patients treated with MTX had lower radiographic progression than 
patients with other DMARDs as an anti-rheumatic therapy [28-30] while some earlier 
studies showed that MTX did not slow radiographic progression in patients with established 
RA and more regular monitoring of disease activity was recommended [31, 32]. The 
precise mechanism of action of MTX in treating RA is not clear but it has been shown that 
MTX down regulates synovial inflammation by decreasing synovial machrophages [33]. 
Recently, Revu et al. showed that MTX decreases synovial cellularity as well as RANK 
expression (receptor activator of the NF-kB) and RANKL/OPG (osteoprotegerin) ratio and 
might have a direct effect on bone metabolism in treatment of RA [34]. Data from clinical 
randomized trials showed that in RA patients who did not show adequate effects of MTX as 
a monotherapy, a combination of MTX, Sulfasalazine and hydroxychloroquine had a 
superior effect [35] and a similar result was noticed for the combination MTX and 
Cyclosporin A [36].  
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1.2.3.2 Glucocorticosteroids (GCs) 
GCs were introduced in rheumatology by Hench and Kendall as early as 1948 and the first 
patient with RA was treated with GCs in the same year [37]. GCs are still used today with 
good efficacy. However, long term use of high dose GCs has been discovered to lead 
complications such as hypertension, diabetes and osteoporosis. Systemic administration of 
GCs decreases macrophage numbers and also the number of T-cells and B-cells, probably 
through down regulation of the expression of synovial chemotactic factors and adhesions 
molecules [38, 39]. Intra-articular GC treatment reduces rheumatoid inflammation by 
decreasing synovial cell infiltration and pro-inflammatory cytokine expression. Reduction of 
synovial T-cells, TNF, IL-1-  and VEGF (vascular endothelial growth factor) occur in 
association of with clinical effects [40]. Earlier randomized trials have shown that GCs in low 
dose have protective effects regarding radiographic progression in RA [41, 42].  
 
1.2.3.3 Biological treatment 
Several studies have reported the presence and local synthesis of many cytokines in 
inflammatory rheumatoid synovium [43-46]. Among these, TNF-α was first characterized as 
a factor that induces necrosis of tumor cells and subsequently been recognized to mediate 
numerous inflammatory and immune regulatory activities. In 1993, Elliot et al. presented a 
study in which 20 RA patients who were treated with monoclonal anti-TNF antibodies 
achieved significant clinical and laboratory improvement [47]. One year later, this pilot study 
was followed by a multi-center, randomised double-blind trial with the same anti-TNF 
monoclonal antibody. 73 patients with active RA were recruited and were randomised to low 
or high dose of active treatment compared to placebo. The result showed that blocking of 
TNF was highly effective in the treatment of therapy resistant established RA [48]. The 
efficacy of anti-TNF treatment has now been shown in many controlled trials [49-51]. In 
2000, the use of MTX in combination with Infliximab was shown to be important in 
achieving radiographic results, even better than clinical results. Patients treated with 
Infliximab in combination with MTX achieved complete inhibition of radiographic 
progression at the group level [52]. Later studies supported the use of anti-TNF therapy in 
combination with MTX in RA patients, demonstrating lesser radiographic progression as 
compared to any agent alone. Breedveld et al in the PREMIER trial showed that RA patients 
treated with Adalimumab in combination with MTX had significantly less radiographic 
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progression, compared to patients in MTX or Adalimumab monotherapy arms [53]. Similar 
studies have now demonstrated the same result with other anti-TNF agents [49, 54, 55].  
Bedsides TNF blocking, B-cells depletion using Rituximab has proved to be another 
successful therapeutic approach in RA patients.  B-cells play an important role in 
immunopathogenesis of RA, such as autoantibody production and antigen presentation [56-
58]. Rituximab is a chimeric monoclonal antibody directed against CD20 antigen expressed 
by B-cells. Repeated treatment with Rituximab has been shown to have sustained clinical 
response, good tolerability and safety in RA patients, however with somewhat reduced 
radiographic efficacy compared to anti TNF treatment [57, 59, 60].   
The inhibition of T-cell activation has also been shown to be efficient in the treatment of both 
anti TNF naïve RA patients and those who had response failure to these drugs [61, 62]. 
Abatacept, a CTLA 4-Ig fusion protein down-regulates T-cell activation by inhibiting the 
CD80/96:CD28 co-stimulatory pathway that is required for full T-cell activation [63]. 
Kremer et al. showed in a 3 years open-label part of the AIM study [64] that Abatacept had a 
protective effect on radiographic progression in the majority of RA patients who remained on 
the treatment [65].  
Anti IL-6 therapy (Tocilizumab) has been studied in several controlled trials and showed 
clinical efficacy in RA patients with response failure to prior anti-TNF agents, DMARDs or 
both [66, 67]. Tocilizumab is a humanized anti IL-6 receptor monoclonal antibody which 
binds to circulating soluble and membrane-expressed IL-6 receptor [68]. A recent study by 
Dougados et al showed that treatment with Tocilizumab as add-on or switching therapy in 
patients with MTX as a first treatment and with at least moderate disease activity improved 
both clinical and radiographic response. The majority of patients exhibited minimal 
radiographic progression at 52 weeks [69].  
 
1.2.4 Evaluation and outcomes of patients with RA 
In the assessment of RA, it is necessary to bear in mind that the disease has several facets that 
need to be captured. The three main areas of disease outcomes are disease activity, joint 
damage or radiographic destruction and functional impairment. At the same time, there is 
significant association between these elements and quality of life, co-morbidity and mortality 
[70]. Disease activity reflects different underlying variables that can fluctuate during the 
disease course spontaneously or upon treatment and it is reflected by using the core set of 
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measures. At the same time, radiological destruction and functional disability should be 
considered for assessment of disease outcomes and treatment decision is made since joint 
damage and a part of functional disability are permanent abnormalities and can no longer be 
improved.  
 
1.2.5 Assessment of disease activity 
As joint involvement is a fundamental hallmark for RA, it is therefore necessary to assess 
joint involvement regularly. In both the ACR and EULAR core sets of disease activity, the 
number of swollen and tender joints is included. Another reliable instrument is measuring 
acute phase reactant (ESR and CRP), the most frequently used biomarkers. These 
measurements should be done in conjunction with both clinical symptoms/signs assessment 
and patient self-assessment of global disease activity.                                                      
Disease activity score (DAS) was the first composite measurement developed to assess 
response to treatment (DMARDs) and also to compare RA patients in groups. DAS includes 
44 swollen joint count, Ritchie articular index [71], ESR and visual analogue scale (VAS) for 
patient global self-assessment of disease activity [72]. DAS28 was introduced as a simplified 
version by Prevoo et al. and includes 28 joint counts for tenderness and swelling, ESR and 
patient global self-assessment of disease activity [73]. DAS28 has also been modified to 
include CRP instead for ESR (DAS28-CRP) [74] or to exclude patient global assessment of 
disease activity (DAS28-3) [75]. Simplified Disease Activity Index (SDAI) and Clinical 
Disease Activity Index (CDAI) are likely simpler instruments to measure disease activity by 
using reduced joint count and simple indices. They provide validated outcomes when 
assessing RA for disease activity and response to treatment [76]; however they have more 
stringency in defining remission [77, 78].  
 
1.2.6 Radiographic progression in RA  
As one of the goals of RA therapy is to prevent or retard joint damage as well as maintaining 
a good functional status, it is important to know how patients who respond well clinically to 
the treatment do at later follow-ups and, even more importantly, whether they progress 
radiographically or not. It is known that bone destruction during the disease course correlates 
with functional disability and decline in quality of life [79, 80] so one of the most important 
challenges in RA is to identify those patients who are likely to develop significant 
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radiographic progression. Several predictive factors for radiographic progression, including 
presence of anti-cittrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF), 
baseline level of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and 
presence of bone erosions at the beginning of the disease have been identified before [81-83]. 
Accordingly, several studies have attempted to construct clinically useful risk matrices to 
predict so-called rapid radiographic progression (RRP), corresponding to an increase in the 
Sharp van der Hejde score (SHS) of ≥5 after 1 year and the performance of these matrices has 
been tested on both early and unselected RA population [84-88]. For patients who are likely 
to develop radiographic progression, it is possible that it is necessary to choose more potent 
therapies than MXT as a monotherapy or necessary to follow up them more regularly in the 
beginning of the disease as recommended by the EULAR guidelines which state that joint 
damage should be assessed by X-rays of the hands and the feet every 6–12 months during the 
first few years [89].  
 
1.2.7 Conventional radiography 
Conventional radiography has been the most common and one of the least expensive imaging 
modalities for the evaluation of patients with rheumatologic disorders. In RA, the 
radiographic assessment of the bone and cartilage includes: 
- The presence or absence of bone loss or destruction 
- Joint space narrowing  
- Change in bone mineral density 
- Subluxation, dislocation, ankylosis and complete luxation 
Serial radiography can help us with staging, monitoring and assessment of treatment efficacy. 
Validated scoring methods of radiographic damages have been developed and are used 
mostly in clinical trials [90]. As conventional radiography is suitable to detect cortical bone 
damage, it is very useful for follow-up and monitoring of established RA. An important 
limitation of the method is the inability to detect early stages of inflammatory process [91, 
92].   
 
 
 9 
 
1.2.7.1 Sharp score modified by van der Heijde: 
In 1971, John Sharp proposed a method for scoring of erosion and joint space narrowing in 
the hands [93] and the first description included 27 areas (all joints in the hands and carpus) 
scored for erosion and joint space narrowing. A new study in 1985 resulted in 17 areas read 
for erosion and 18 areas read for joint space narrowing in each hand [94]. The main limitation 
of Sharp score is that the feet are not included and as we know, joints in the feet are 
frequently involved in RA and even sometime before hands [8]. Because of this reason Sharp 
score from 1985 was modified by van der Heijde et al to include scoring of the feet and 
moreover one site for erosion and 3 sites for joint space narrowing were also excluded from 
the hands [95, 96].  
Sharp score modified by van der Heijde (SHS) method is a combination of erosion and joint 
space narrowing score. The erosion score for one joint in the hands ranges from 0 to 5. The 
score of 1 is given if the erosion is small and erosion is scored 3 if it extends more than 50% 
over bone surface. Complete collapse of the bone is scored as 5. Joint space narrowing has a 
range between 0 and 4 and is combined with the score for (sub)luxation. A score of 3 is given 
if the joint space is decreased more than 50%. Bony ankylosis and complete luxation is 
scored as 4.  Figure 1 demonstrates a description of scoring system and the sites of 
assessment in the hands. In the feet, the assessment is applied to the 10 metatarsophalangeal 
(MTP) and 2 interphalangeal (IP) joints as it is demonstrated in figure 2. The maximum 
erosion score in feet is 10 instead of 5 [95].  
 
FIGURE 1: Sites of assessment and scoring system in the hands according to the Sharp score 
modified by van der Heijde. Left: Sites for assessment of joint space narrowing score, 
middle: Sites for assessment of erosion score, right: examples for erosion score. 
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FIGURE 2: Sites and surface of assessment in the feet according to the Sharp score modified 
by van der Heijde. Left: Sites for assessment of joint space narrowing score, middle: Sites for 
assessment of erosion score, right: examples for erosion score.  
 
The total erosion score of all joints in the hands is 160 points and in both feet is 120 points. 
The maximum score for joint space narrowing score in the hands is 120 and in the feet 48. It 
is important to note that the maximum erosion score in the joints of the feet is higher (10 
instead for 5) and this may influence a total score of both hands and feet but on the other side, 
the total number of scored sites in the hands is greater and this counter-weighs the higher 
score for each joint in the feet. 
 
1.2.8 Radiographic progression and choice of treatment 
Although MTX is still the first line treatment of choice in RA according to the EULAR 
guidelines [97] several studies have shown that combination therapy with GCs, other 
DMARDs or biologic agents is superior to MTX as monotherapy, specially to prevent or 
retard radiographic progression [35, 42, 53, 98-100]. Svensson et al in 2005 showed that in 
patients with early RA, prednisone in low doses when added to initial DMARD retarded 
radiographic progression after 2 years [42]. In a multicenter, randomized double-blind 
clinical trial (PREMIER study), Breedveld et al showed that combination therapy with MTX 
and Adalimumab was superior to MTX monotherapy, regarding all outcomes measured. 
Radiographic progression was significantly lower in patients with combination treatment 
compared to those with MTX monotherapy and even Adalimumab as a monotherapy [53] as 
shown in figure 3. A similar result was presented by Emery et al in the randomized double-
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blind trial in 542 MTX naïve RA patients with moderate to high disease activity. 80% of 
patients who were treated with combination MTX and Etanercept had no radiographic 
progression (Delta SHS score < 0.5 point) after one year while this value for MTX 
monotherapy was 59%, figure 4. 
 
 
FIGURE 3: Radiographic progression according to SHS score over 2 years in PREMIER 
trial 
 
 
 
FIGURE 4: The proportion of patients with no radiographic progression in COMET trial. 
*p= 0.0001 
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1.2.9 Smoking and radiographic progression in RA 
It is known that RA patients who smoke have more severe disease and poor prognosis, 
compared to those who do not smoke. Smoking status at the time of diagnosis predicts higher 
disease activity with more prominent featuring of articular involvement from the disease 
onset, higher level of inflammation detected by acute phase reactant and more radiographic 
damage [101, 102]. Current smoker RA patients are less likely to respond to the treatment 
with DMARDs or biologic agents [103].  RA patients who are current smokers also have 
increased risk for developing severe extra-articular manifestation [104]. Current smoking at 
disease onset increased the risk for extra-articular manifestation 2.8 times more in current 
versus non-smokers and 4.1 times more in current versus never smokers. As mentioned 
previously, many predictive factors for radiographic progression have been identified before 
and several studies have attempted to construct clinically useful risk matrices to predict so-
called rapid radiographic progression (RRP), however, none of these studies has evaluated 
whether smoking habits associate with RRP.  
 
1.3 DIGITAL X-RAY RADIOGRAMMETRY 
Bone mineral density (BMD) is calculated as bone mass divided by a projection area, figure 
5. BMD is divided into cortical, trabecular and total bone mineral density. There are several 
non-invasive methods for the measurement of bone density status both axially and 
peripherally and considerable advances have been made during the last 3 decades. These 
methods include dual X-ray absorptiometry (DXA), quantitative computed tomography 
(QCT) quantitative ultrasound (QUS) and digital X-ray radiogrammetry (DXR) [105-107]. 
These quantitative bone measurements are demonstrated in details in table 3 [108].  
 
FIGURE 5: BMD = Bone mass / projection area. Larger bones have larger BMD  
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TABLE 3: Quantitative bone mineral measurement 
 
Periarticular osteopenia is one of the earliest radiographic features of RA that can be 
detected by conventional radiography of the hands and feet [109, 110] and it reflects a 
reduction in BMD and may precede erosion and joint space narrowing [110].  Periarticular 
osteopenia may be caused by local release of inflammatory mediators and immobility [109, 
111]. The sensitivity of conventional radiography regarding osteopenia is limited, as it can 
only be detected if the reduction of bone density is more than 35-50% [112, 113]. 
Quantitative measurement of hand bone loss that captures periarticular osteopenia has been 
proposed as a predictor or an outcome measurement in RA [114, 115]. For measurement of 
BMD in the hands in patients with early RA, DXR (a computerized version of an earlier 
technique of radiogrammetry as originally proposed by Barnett and Nordin [116]) has been 
shown to be superior to DXA [112]. Some previous studies have compared total bone loss 
measured by DXA and cortical bone loss measured by DXR in the hands of patients with 
RA [112, 117, 118].  
 
 
FIGURE 6: Loss of bone mass (thinning) in the cortical bone 
 
Method Type of measurement
DXA Total cortical and trabecular bone
DXR Cortical bone only
QCT Cortical and trabecular bone separately
QUS Measurement that reflects bone quality
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The DXR technique measures cortical BMD in the diaphysis of 2
nd
, 3
rd
 and 4
th
 metacarpal 
bones through the conventional radiography of the hands. The measurement of the total and 
medullar width of the bone is used to quantify cortical BMD changes over time, figures 6 
and 7 [109]. In recent years studies have been presented on ascertaining whether patients 
with RA exhibit inflammation-related osteopenia using DXR [109, 117, 119-121].  
 
 
FIGURE 7: Digital X-ray Radiogrammetry, analysis of hand 
 
Bottcher et al in 2005 showed that DXR estimated severity-dependent cortical BMD 
reduction in RA patients, independent of therapy with steroids. In 96 patients with RA, 
calculations of DXR-BMD, metacarpal index by DXR and BMD measurement of distal 
radius by QCT was performed. Correlation between DXR-BMD and metacarpal index versus 
QCT was significant, independent of steroids therapy. The highest correlation was observed 
between metacarpal index and total QCT. No significant association between DXR-BMD and 
cortical QCT was observed in patients without steroids intake. There was also shown to be a 
significant association between severity of RA and reduction of DXR-BMD and metacarpal 
index. So the results indicated a reduction of DXR parameters with an increase in the severity 
of RA [109].   
Hoff et al in 2007 showed that hand bone loss (HBL) measured by DXA seems to occur only 
in the first 3 years of RA whereas DXR-BMD loss occurs both in the early and late stage of 
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the disease. DXR for measurement of cortical BMD and metacarpal index was performed in 
215 RA patients; DXA was used to measure the whole hand BMD (both cortical and 
trabecular). Data for disease activity and anti-rheumatic treatment were also collected. RA 
patients with high disease activity during the early stages of their disease had more DXR-
BMD loss than patients with low disease activity. This means disease activity independently 
predicted DXR-BMD reduction and not changes in DXA-BMD. A significant association 
between DXR-BMD and the metacarpal index was also observed [117].  
The question that was investigated in later studies was whether HBL in early stages of RA 
could predict radiographic damage later in the disease course. A study by Hoff et al in 2009 
showed that HBL as measured by DXR predicted later radiographic damage after 5 and 10 
years. 136 patients with RA were followed for 10 years, radiographic damage was assessed 
by Sharp score modified by van der Heijde (SHS) and HBL was measured by DXR. A least 
significant change (LSC) of BMD (0.78% in the study of question) was used as a cut-off for 
hand bone loss. Patients with HBL at one year had higher median SHS-score at 5 and 10 
years. In a linear regression model adjusted for clinical and laboratory data, HBL was an 
independent predictor for radiographic damage at 5 and 10 years [120]. 
 
A similar study by Forslind et al showed the same results. In 166 patients with early RA, 
radiographic damage was scored according to the SHS at baseline, 1 and 2 years. BMD in the 
FIGURE 8: Change in SHS score at 5 
years (A) and 10 years (B) in patients 
with RA  stratified for HBL at 1 year 
[cut-off >LSC (0.78%)].  
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diaphysis of 2
nd
, 3
rd
 and 4
th
 metacarpal bones was measured on a standard radiograph of the 
hand using DXR. The definition of HBL was change in BMD-DXR during the first year of 
more than 0.0048 g/cm
2
 that was LSC used by Hoff et al [120]. Smallest detectable change 
was also used as the definition of radiographic progression (5.8 point according to the SHS). 
An interesting result in that study was that HBL was observed more often in patients without 
steroid therapy compared to those with steroid therapy (83% versus 44%, p=0.001). HBL 
during the first year was an independent predictor for radiographic damage at 1 and 2 years, 
using multiple logistic analyses [119].  
Another similar study in 2011 also demonstrated that early BMD loss between two available 
radiographs (4-16 months), measured by DXR predicted radiographic progression according 
to the Larsen score [122] at 1 year and up to 20 years in the cohort of early RA patients. 183 
patients with early RA were included between 1985 and 1989 in the south of Sweden. The 
definition of HBL was BMD reduction measured by DXR more than median for the group 
[121].  
 
 
Kapetanovic et al. Arthritis Research & Therapy 2011, 13:R31 
http://arthritis-research.com/content/13/1/R31 
FIGURE 9: Radiographic progression according to the Larsen score over time after 
stratification according to the median (-0.0185 g/cm2 per year) of early BMD measured by 
DXR.  
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Another potential application of DXR as a non-invasive imaging modality in RA is 
possibility to use it for treatment monitoring. In the BeSt study, 508 patients with early RA 
were included and were allocated to one of four therapies: Sequential monotherapy (group 1); 
step-up monotherapy (group 2); initial combination therapy with tapered high dose 
prednisone (group 3) and initial combination therapy with Infliximab (group 4). The disease 
activity was scored every 3 months according to DAS44 [99]. 218 of 508 patients with hand 
radiographs and DXA measurements of the hip and the lumbar spine at baseline, 1 and 2 
years follow-up were included to investigate the effect of different anti-rheumatic therapies 
on BMD in the hands, hip and spine. BMD of the hands was measured by DXR. Patients with 
initial monotherapy had significantly more HBL than patients on initial combination therapy 
and progression in erosion score was independently associated with bone loss both in the 
hands and hip after 1 year. The study concluded that there were common pathways between 
radiographic progression and both HBL and generalized BMD loss [123].  
 
 
 
FIGURE 10: The mean BMD loss and SHS erosion score in 4 treatment groups in the BeSt 
study.  
 
In the PREMIER study, HBL was also less pronounced in patients with combination therapy 
and significant differences in HBL and radiographic progression were seen between 
combination therapy (Adalimumab + MTX) and MTX monotherapy at 12 and 24 months 
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follow-up as shown in figure 11 [124]. The key finding of the study was the role of anti-TNF 
treatment in combination with Methotrexate in bone protection; however the effect of 
combination therapy on HBL was not as great as for radiographic progression. 
 
 
 
FIGURE 11: Change over 2 years in DXR metacarpal index and SHS score in 3 different 
therapy groups in PREMIER study 
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1.4 MUSCULOSKELETAL ULTRASOUND 
Musculoskeletal ultrasound (MSUS) is being used increasingly in diagnosis and management 
of inflammatory arthritis in recent years. This change is driven by the need: 
-To diagnose synovitis and other inflammatory conditions as early as possible.  
-To monitor and follow-up the disease activity more accurately in order to achieve 
sustainable suppression of inflammation.  
MSUS is a reliable, cost effective, patient friendly and safe imaging modality used as a 
complement to other diagnostic methods in rheumatology and it has been shown to be 
superior to clinical examination to identify synovitis [92, 125-128]. The validity of MSUS in 
detecting synovitis and other inflammatory pathologies in rheumatology has been shown in 
several studies [125, 127-130]. 
1.4.1 The role of MSUS in inflammatory arthritis: 
In rheumatology, it seems to be necessary that imaging modalities should be available to 
provide immediate and accurate clinical information without compromising patient safety. 
MSUS is an imaging technique in this category [131] specifically in combination with the 
development of high-frequency transducers and the improvement of the software and 
hardware for ultrasound equipments. Table 4 shows a summary of the role of MSUS in 
inflammatory arthritis. 
 
Table 4: Application of MSUS for assessment and management of inflammatory arthritis 
 
Early detection of synovitis and other inflammatory conditions in RA and other arthritic 
disorders seems to be the most important and fundamental application of MSUS in order to 
accurately diagnose, manage and follow-up the disease.  
Summary of the role of MSUS in rheumatology
Detection and assessment of synovitis and other inflammatory conditions
Detection and evaluation of bone erosion
Ultrasound guided procedure
Remission assessment
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In 2005, OMERACT (Outcome Measures in Rheumatology Clinical Trials) and EULAR 
working groups on MSUS published an expert consensus on ultrasonographic definitions for 
methodological approaches in various inflammatory pathological processes as shown in table 
5.  
 
Table 5: Typical pathological findings detected by MSUS according to OMERACT [132] 
 
 
FIGURE 12: Scanning of the anterior knee on long- and short axis, showing effusion in the 
supra-patellar fossa (obtained by the author) 
Pathology Definition
Effusion Abnormal hypoechoic or anechoic intra-articular material that can be 
displaced and compressed, but does not exhibit Doppler signals (figure 12)
Synovial hypertrophy Abnormal hypoechoic intra-articular tissue that is non-displaceable and 
poorly compressible and which may exhibit Doppler signals (figure 13)
Tenosynovitis Hypoechoic or anechoic thickened tissue with or without fluid within the 
tendon sheath with possible signs of Doppler signals, which is seen in two 
perpendicular planes (figure 14)
Bone erosion An intra-articular discontinuity of the bone surface that is visible in two 
perpendicular planes (figure 15)
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FIGURE 13: Dorsal longitudinal scanning of the 2
nd 
MCP joint in a patient with RA, 
showing synovial hypertrophy with intra-articular hyperemia. (obtained by the author)  
 
 
FIGURE 14: Volar transversal and longitudinal scanning of the wrist, showing tenosynovitis 
of flexor digitorum profundus tendons. (obtained by the author) 
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FIGURE 15: Radial longitudinal scanning of the 2
nd
 MCP joint in a patient with RA. The 
images show erosion in the metacarpal head with active Doppler signals implying active 
erosive disease (obtained by the author). 
 
As Kelly et al showed routine use of MSUS for patients with suspected inflammatory arthritis 
was associated with earlier diagnosis and earlier initiation of therapy in patients with RA as 
final diagnosis. In that study, 258 patients from four centers in the United Kingdom were 
included and divided into two groups, those who were diagnosed by MSUS versus those who 
were not. A significantly greater proportion of patients in the MSUS group received a final 
diagnosis at their first visit and a similar difference was observed for patients with a diagnosis 
of RA. Where patients had a diagnosis of RA, there was a significant difference in the time to 
diagnosis and time to initiation of therapy.  That study showed that routine use of MSUS in 
newly referred patients was associated with earlier diagnosis and earlier DMARD initiation in 
patients with RA [133]. As is known, earlier diagnosis and treatment of RA leads to better 
outcomes. A study by van der Lindel et al showed that assessment in less than 12 weeks was 
associated with less joint destruction and a higher chance of achieving DMARD-free 
remission as compared with a longer delay in assessment [134].  
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Several previous studies have shown the usefulness of MSUS in early detection of synovitis, 
tenosynovitis and joint effusion in different anatomical sites. Backhaus et al showed in 1999 
that MSUS was as sensitive as MRI for detecting synovitis in finger joints whereas MRI 
detected erosion more often. Synovitis in finger joints was detected by MSUS in all patients 
with (32 patients, 448 finger joints) and without (28 patients, 392 finger joints) radiographic 
signs of destructive arthritis [125].  
Kane et al in 2003 showed that MSUS was more sensitive than clinical examination to detect 
effusion, supra-patellar bursitis and Baker´s cysts in patients with RA. A total of 44 knees 
were examined in 130 sites both by MSUS and clinically. MSUS detected 61% of knee joint 
effusion whereas 36.4% of which were detected by clinical examination. The similar 
difference was also observed in detection of Baker´s cysts and supra-patellar bursitis [135]. 
This indicates the confirmation of MSUS as a more sensitive and specific method to detect 
knee joint effusion. In another study that was conducted on 60 patients being examined for 
knee synovitis, MSUS was shown to be more accurate than clinical examination to detect 
synovitis in the knee. In that study, with the use of arthroscopy as a gold standard for 
detecting of knee synovitis, MSUS had a higher sensitivity (98% versus 85%), specificity 
(88% versus 25%), accuracy (97% versus 77%), positive predictive value (98% versus 88%), 
and negative predictive value (88% versus 20%) compared with clinical examination. At the 
same time, the Cohen kappa values for inter-observer and intra-observer reproducibility of 
MSUS for distinguishing between presence and absence of synovitis were 0.71 and 0.85, 
respectively (P < 0.05 for both). That study confirmed the validity of MSUS as a useful and 
reproducible modality for detection of synovitis in the knee [130]. 
The validity of MSUS to detect signs of synovitis and bone destruction in finger joints has 
also been assessed in previous published studies. In 2006, Szkudlarek et al performed a study 
on 40 RA patients and 20 healthy controls to investigate sensitivity and specificity of MSUS 
in detecting synovitis and erosions in MCP and PIP joints 2-5. MSUS was assessed in 
comparison with MRI as a gold standard. Agreement between MSUS and MRI regarding the 
presence or absence of synovitis was achieved in 76% of the examined finger joints. The 
sensitivity, specificity and accuracy of MSUS for detection of synovitis, compared with MRI 
as the reference, were 0.70, 0.78 and 0.76, respectively whereas these parameters for clinical 
examination were 0.40, 0.85 and 0.72, respectively. Similar results were shown for bone 
erosions, consistent with a study, performed by Wakefield et al in 2000 [136]. The conclusion 
of that study was that MSUS was more sensitive than clinical examination in assessing signs 
of inflammation, with only a slight loss of specificity [127]. A similar study with focus on 
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MTP joints also showed that MSUS was significantly more accurate than clinical 
examination for the detection of synovitis and more accurate than conventional radiography 
for the detecting of bone erosion. The sensitivity, specificity, and accuracy of MSUS for the 
detection of synovitis in MTP joints were 0.87, 0.74, and 0.79, while for clinical examination, 
the corresponding values were 0.43, 0.89, and 0.71 respectively [128]. 
 
1.4.2 Diagnostic utility of MSUS in early inflammatory arthritis: 
Musculoskeletal complaints are exceedingly common in the population and a large 
proportion of patients with severe, refractory, or unclear joint symptoms are referred to 
rheumatology units for further diagnostic evaluation. The traditional evaluation of patients 
with joint symptoms primarily used to include medical history and physical examination, 
complemented by blood tests including rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA), synovial fluid examination, and radiography of affected joints [8, 20]. 
Although the traditional methods are well established, there are still a sizeable proportion of 
patients in this category who are not reliably diagnosed in the early stages of the disease. 
Thus more sensitive and accurate complementary methods seem to be needed. As mentioned, 
the validity of MSUS for detecting of synovitis has been confirmed by several studies before. 
However, quantitative analyses of the diagnostic utility of MSUS in patients with 
inflammatory arthritis in rheumatologic practice have been done in smaller groups of patients 
[137-139]. A study based on a retrospective analysis of clinical datasets from an early 
arthritis cohort in the United Kingdom showed that MSUS provided no additional 
discriminatory value to predict persistent inflammatory arthritis [140]. In that study, MSUS 
as a routine supplement in early arthritis patients did not add any substantial discriminatory 
value for predicting persistent inflammatory arthritis. Among 379 patients, seven clinical and 
serological variables had independent and significant associations with persistent arthritis. 
MSUS was performed on 16 peripheral joints in the hands and feet (wrist joints not included). 
A risk metric derived from 12 baseline clinical and serological parameters alone had an 
excellent discriminatory utility with respect to diagnosis of inflammatory arthritis (area under 
ROC curve 0.91; 95% CI 0.88 to 0.94). The discriminatory utility of a similar metric, which 
incorporated MSUS parameters, was not significantly superior (area under ROC curve 0.91; 
95% CI 0.89 to 0.94). Neither did this approach identify any added value of MSUS over the 
use of routine clinical parameters in an algorithm for discriminating inflammatory arthritis 
patients whose outcome diagnosis was RA as shown in figure 16 [140].  
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Pratt et al. Arthritis Research & Therapy 2013 15:R118 
    
Freestone et al in 2010 showed that combination of power Doppler ultrasound with 
conventional assessment in patients with seronegative inflammatory arthritis had a major 
impact on diagnostic certainty. 50 patients with inflammatory symptoms in the hands 
(stiffness > 1 hour with or without clinical synovitis) were recruited consecutively. All 
patients with positive ACPA and RF developed persistent inflammatory arthritis at 12 
months. The diagnosis was obtained by a rheumatologist who was blinded to the MSUS 
results. MCP joints, both wrist and flexor tendons were scanned by MSUS. The likelihood of 
inflammatory arthritis in seronegative patients was 6% while adding clinical and radiographic 
information raised the probability to 30% and with certain MSUS findings this rose to 94%. 
That study addressed the diagnostic utility of MSUS in patients with early arthritis [139].  
 
1.4.3 MSUS scoring systems: 
Monitoring of disease activity in RA is provided by different clinical scoring systems [73, 
76]. Some of these methods are used in clinical praxis and others for research purposes 
primarily to measure disease activity and to monitor response to treatment. However, clinical 
scoring systems have some limitations. Despite clinical remission, subclinical activity may 
sometimes be observed leading to radiographic progression [141, 142]. Therefore, more 
FIGURE 16: ROC curve for 
discriminatory utility of predictive 
metric for RA among patients 
with persistent IA.   
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sensitive methods seem to be needed to assess the disease activity and to evaluate response to 
therapy. During recent years, MSUS has become an important imaging modality in 
rheumatology serving this purpose. Thus, standardization of ultrasound results has become 
essential.  
Ultrasound results in different joint areas can be scored binary (0/1), semi-quantitatively (0-3) 
or quantitatively in B-mode as well as in Doppler.  
The first scoring system for erosions in RA was described by Wakefield et al in 2000 [136]. 
The measurement of erosion was as follow: normal: < 2 mm, small erosion: = 2 mm, 
moderate erosion: >2 <4 mm and large erosion > 4 mm. The Kappa value between two 
observers was at least 0.76 for present/absent erosions and most erosions were observed in 
the radial or ulnar aspects of MCP joints 2 to 5. 
Szkudlarek et al described 4-grade scoring system for joint effusion, synovitis, bone erosions, 
and intra-articular power Doppler signals in 2003 [143]. Joint effusion was described as an 
intra-articular anechoic compressible area (0 = no effusion, 1 = minimal, 2 = moderate 
without distension of joint capsule and 3 = extensive amount of effusion with distension of 
joint capsule). He described synovitis as a hypoechoic intra-articular non-compressible area 
(0 = no synovial thickening, 1 = minimal without bulging over the line linking tops of the 
bones, 2 = synovial thickening with bulging over the line linking tops of the periarticular 
bones but without extension along the bone and 3 = synovial thickening with both bulging 
over the line linking tops of the periarticular bones and with extension to at least one of the 
bones). Szkudlarek et al described bone erosions in a different way compared to Wakefield et 
al. The definition of bone erosions was: 0 = normal regular bone surface, 1 = irregularity 
without defect formation, 2 = bone defect formation which is seen in 2 perpendicular planes 
and 3 = bone defect with extensive destruction. Intra-articular Doppler signals were defined 
as 0 = no signals in the synovium, 1 = single vessel signals, 2 = confluent signals in < 50 % 
of synovial area and 3 = signals in > 50 % of synovial area (figure 17).  
Scheel et al introduced in 2005 a summary of ultrasonographic synovitis scoring systems 
suitable for evaluation of finger joint inflammation in RA [161]. The study was also a 
comparison of semi-quantitative MSUS scoring with quantitative MSUS measurements. 
Dorsal and palmar ultrasound scans were performed on the second to fifth MCP and PIP 
joints in 10 healthy controls and 46 RA patients with arthritis in the hands.  Synovitis was 
standardized and scored semi-quantitatively and also compared with quantitative method. 10 
patients underwent additional MRI of the hands and results were compared with both semi-
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quantitative and quantitative ultrasound measurements. Grade of inflammation (effusion and 
synovial hypertrophy combined) was scored between 0 and 3 (no effusion or hypertrophy to 
extensive effusion or hypertrophy). In that scoring system, the grade of both effusion and 
synovial hypertrophy was measured and evaluated as described by Szkudlarek et al [143] but 
for simplification in clinical practice, both joint effusion and synovial hypertrophy were 
combined in one measurement and adapted to the scoring system as described above (figure 
18).  
 
 
FIGURE 17: Dorsal longitudinal scanning of MCP joints in patients with RA, showing 
different grade of color Doppler signals (obtained by the author) 
Grade 0 
Grade 2 
Grade 1 
Grade 3 
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FIGURE 18: Dorsal Longitudinal scanning of MCP joints in RA patients, showing different 
grade of synovial hypertrophy/joint effusion (score 0-3) according to the scoring system by 
Scheel et al. (obtained by the author) 
  
Grade 0 
Grade 1 
Grade 2 
Grade 3 
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2 AIM OF THE THESIS 
 
2.1 GENERAL AIM 
The overall aim of this thesis was to study the role of three imaging modalities; 
conventional radiography, digital X-ray radiogrammetry and musculoskeletal ultrasound in 
diagnosis and management of rheumatoid arthritis.  
 
2.2 SPECIFIC AIMS 
1. To evaluate the clinical and radiological outcomes of early RA patients who initially 
responded well to MTX and follow up in regular care during the first 2 years of the disease 
course (study I). 
 
2. To determine whether hand bone loss analyzed by DXR during first year correlated with 
radiographic progression, as measured by Sharp score modified by van der Heijde, after 2 
years in early RA patients and to compare HBL and radiographic progression in the three 
treatment groups of the SWEFOT trial (study II). 
 
3. To evaluate whether baseline predictors, such as smoking habits, are associated with 
rapid radiographic progression one year after diagnosis of RA in the SWEFOT trial (study 
III). 
 
4. To assess the diagnostic impact of musculoskeletal ultrasound findings in patients 
referred for rheumatologic evaluation because of suspected arthritis (study IV).  
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3 MATERIALS AND METHODS 
This thesis is based on four epidemiological clinical studies. The first 3 papers are based on 
the SWEFOT (SWEdish PharmacOTherapy) clinical trial and the last paper is an 
observational prospective study with focus on the role of musculoskeletal ultrasound in 
patients with suspected arthritis.  
 
3.1 SWEFOT trial (paper I-III) 
The SWEFOT trial was collaboration between 15 rheumatology units in Sweden between 
2002 and 2008. Adult patients diagnosed with RA according to the revised ACR criteria 
[17] with symptom duration less than 12 months were included in the trial. They had no 
previous treatment with DMARDs, nor oral GCs or stable dosage of GCs for at least 4 
weeks of, at most, 10 mg Prednisone or equivalent. Disease activity was measured by a 
rheumatologist using DAS28 [73]. A score of >3.2 was required to be included in the trial. 
The main exclusion criterion was contraindications to any trial drugs. 
 
  FIGURE 19: Schematic of the SWEFOT trial 
SWEFOT trial
Rheumatoid arthritis
Symptom duration < 1 yr
No previous DMARD use
DAS28 > 3.2 
Methotrexate monotherapy
Dosage: 20 mg weekly
3-4 months
Baseline:
N=487
Clinical assessment and 
randomisation of patients
with DAS > 3.2 
3 months
Patients with good clinical response 
to MTX and DAS28 < 3.2
N=147
MTX + INF
N=128
MTX + SSZ + HCQ
N= 130
X-Ray of the hands and feet was performed at baseline, one and two years. 
Radiographic damage was measured according to the Sharp score modified by van der Heijde.
MTX monotherapy and 
follow-up according to 
the standard care
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After given informed consent and inclusion, all patients were treated with MTX at the 
initial dosage of 10 mg weekly. This dose was increased every 2 weeks by 5 mg increments 
up to 20 mg a week. Folic acid supplements in tablets of 5 mg were prescribed to be taken 
1–6 times a week, but not on the day of intake of MTX. Liver enzymes and blood counts 
were monitored frequently at first and at wider intervals as time went by, in accordance 
with Swedish guidelines. Abnormalities in these measures could lead to dose adjustments, 
all based on well established clinical routines. Radiographs of hands and feet were obtained 
at baseline, 1 year, and 2 years in accordance with current practice guidelines in Sweden. 
Radiographic progression was evaluated according to the Sharp score modified by van der 
Heijde (SHS) by two certified readers. At 3-4 months follow-up, patients with an 
incomplete response (DAS>3.2) to MTX monotherapy were randomized to two different 
treatment strategies as shown in figure 19. The patients who responded well to MTX 
monotherapy at the 3-4 months follow-up (DAS28<3.2) did not enter the randomization 
and were no longer, technically, part of the SWEFOT trial. These patients were followed in 
standard care. 
 
3.2 Diagnostic utility of MSUS in patients with suspected arthritis (paper IV) 
One hundred and three patients who had been referred to the early arthritis clinic at the 
Karolinska University Hospital by general practitioners were recruited consecutively between 
2010 and 2013 in this study. All patients had suspected inflammatory arthritis but had no 
prior rheumatologic diagnosis. A first clinical assessment was performed by a rheumatologist, 
based on medical history, physical examination, and review of previously performed 
laboratory and/or radiological studies. The assessment was usually complemented by new 
blood tests including ACPA, RF and/or acute phase reactants. Radiographic assessment of the 
hands and feet was also performed. No MSUS assessment was done at the first visit. At this 
time point, the patients were invited to participate in the study and after informed consent was 
given, the rheumatologist completed the study case-report form (CRF) which included: 
-  Likelihood that the patient had inflammatory arthritis 
-  Likelihood that the patient had RA  
In the pre-test assessment, the physician based likelihood on a five-point scale: Very likely 
(probability > 80%), likely (> 60 and < 80%), possible (> 40% and < 60%), not likely but 
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possible (> 20% and < 40%) and very unlikely (< 20%). During one week after the first visit, 
MSUS evaluation was performed by one ultrasound specialist (the author) and the result 
subsequently was presented to the same rheumatologist for post-test assessment. Importantly, 
the MSUS findings including B-mode and color Doppler ultrasound (CDUS) was given 
descriptively as morphological and vascularisation data of the studied joints and not just 
positive or negative findings. The post-test evaluation was performed by the same 
rheumatologist based on clinical and MSUS finding on the same five-point scale. The final 
diagnosis and anti-rheumatic treatment that the patients had been given during a follow up of 
1 to 4 years was studied at the end of the follow up time.   
 
FIGURE 20: Schematic of the study IV 
 
  
Pre-test assessment:
- Based on clinical signs and symptoms, 
blood tests and X-ray
MSUS evaluation:
- Scanning of the hands and feet 
- Scanning of the symptomatic joints
Post-test assessment:
- Based on clinical and MSUS finding
Follow-up, 1-4 years:
- Final diagnosis
- Anti-rheumatic treatment
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4 RESULTS 
4.1 Paper I 
In early rheumatoid arthritis, patients with a good initial response to 
methotrexate have excellent 2-year clinical outcomes, but radiological 
progression is not fully prevented: data from the methotrexate responders’ 
population in the SWEFOT trial. 
4.1.1 Characterization of the patients 
147 patients of all 487 SWEFOT patients responded well to the initial monotherapy with 
MTX achieving DAS28 value of 3.2 or less at the 3 months follow-up visit. This group of 
patients received regular care and clinical and radiological data were collected up to 2 years. 
Complete 2 years´ follow-up data was retrieved in as many as 110 out of these 147 patients. 
Baseline characteristics of this subgroup of patients did not differ from the whole group. 
 
4.1.2 Clinical follow-up 
Mean (SD) observed DAS28 values were 2.53 (1.02) and 2.25 (0.82) at 1 and 2 years, 
respectively (p=0.03). A LOCF (Last Observation Carried Forward) analysis for patients with 
missing data yielded mean DAS28 values of 2.50 (1.02) and 2.34 (0.85) at 1 and 2 years, 
respectively (p=0.03). The proportions of patients who achieved DAS28 remission after 1 and 
2 years were 59.6% and 71.8%, respectively. 37.4% and 39.4% of patients achieved 
remission as defined by the SDAI and CDAI measures at 1 year follow-up visit. After 2 
years, the proportions in SDAI/CDAI remission were 41.2% and 43.7%, respectively.  
TABLE 6: EULAR and ACR responses at 3, 12 and 24 months, left section: based on 
available follow-up data; right section: Patients with missing data imputed as non-responders 
(NRI) 
Responses
3 months
(N=142)
12 months
(N=114)
24 months
(N=110)
3 months
(NRI)
12 months
(NRI)
24 months
(NRI)
EULAR good response 95.1% 76.3% 85.5% 91.8% (135) 59.2% (87) 63.9% (94)
EULAR good or 
moderate response
95.2% 92.1% 97.3% 98.6% (140) 71.4% (105) 72.7% (107)
ACR20 89.6% 83.9% 86.4% 87.8% (129) 63.9% (94) 60.5% (89)
ACR 50 73.6% 70.5% 81.6% 72.1% (106) 53.7% (79) 57.1% (84)
ACR 70 35.4% 41.1% 47.6% 34.7/ (51) 31.3% (46) 33.3% (49)
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The vast majority of patients with complete follow-up data had good EULAR response at 1 
and 2 years follow-up visit, as shown in table 6. 
 
4.1.3 Radiographic follow-up 
Table 7 demonstrates radiographic progression according to the SHS score during follow-up 
time (2 years) in all available patients at each visit and patients with complete radiographic 
data. As shown, the values are almost in the same level in both groups. The mean (SD) 
radiographic progression after 1 year (n=107) was 2.21 (4.15) and after 2 years (n=101) 3.90 
(6.84) (p=0.0003). Progression was seen for both the erosion score and joint space narrowing 
score, with a mean increase at 2 years of 1.40 (4.11) and 2.50 (4.45), respectively, figure 21. 
The definition of no radiographic damage was 0 units according to the SHS score and 48.1% 
of patients had no radiographic damage at the baseline visit. This proportion decreased to 
26.9% and 20.2% after 1 and 2 years, respectively (p<0.0001). No radiographic progression 
was observed in 51.4% and 38.6% of patients at 1 and 2-year follow-up, respectively 
(p<0.0001). A change of one to five units in the total SHS score was seen in 30.8% at 1 year 
and 31.7% at 2 years. Six patients had at least a 10 units increase in total SHS score at 1 year 
and 15 patients had a 10 units or greater increase in the SHS score after 2 years, of whom 11 
patients were still on MTX monotherapy. 
 
TABLE 7: Radiological progression in all available patients at each follow-up visit (left) and 
patients with complete radiological data (right) 
 
Regarding to the radiographic progression, no difference was observed between patients in 
DAS28 remission and other patients. Patients who received other anti-rheumatic treatment in 
combination with MTX or those who switched to other anti-rheumatic treatment during 2 
years follow-up had numerically more radiographic progression compared to those with 
MTX monotherapy (p=0.06).  
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FIGURE 21: Radiological progression in all available patients at each follow-up visit. SHS: 
Sharp score modified by van der Heijde; ES: erosion score; JSNS: Joint space narrowing 
score.  
 
 
4.2 Paper II 
Evaluation of hand bone loss by digital X-ray radiogrammetry as a 
complement to clinical and radiographic assessment in early rheumatoid 
arthritis: results from the SWEFOT trial 
4.2.1 Characterization of the patients:  
159 patients of the SWEFOT trial, with same baseline characteristic as the whole group, had 
radiographs of the hands suitable for DXR analysis, at baseline and 1 year follow-up. The 
distribution of patients with different treatment strategies was almost equal as shown in figure 
22. 
MTX responders had lower baseline DAS28 and better functional status measured by HAQ 
[145] compared with randomized groups (p<0.05 for both DAS28 and HAQ). Regarding to 
the radiographic damage according to the SHS score and bone mineral density (BMD), no 
differences were observed between the three groups at baseline. The definition of 
radiographic progression in this study was an increase more than 5 units according to the 
SHS score during 2 years. Hand bone loss was defined as DXR-BMD change 
rate ≥ 2.5 mg/cm2/month during 1 year. Patients with radiographic progression had higher 
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acute phase reactant (both CRP and ESR) at the baseline while patients with HBL had only 
higher CRP.  
 
 
FIGURE 22: Distribution of patients in paper II with different anti-rheumatic therapies 
 
4.2.2 Bone mineral density measured by DXR 
BMD was measured by DXR at baseline and 1 year follow-up visit. Change in BMD was 
divided into normal (< 0.25 mg/cm
2 
per month), moderately (> 0.25 and < 2.5 mg/cm
2 
per 
month) and highly elevated (> 2.5 mg/cm
2 
per month). The definition of HBL was highly 
elevated BMD change. The proportion of patients with HBL was significantly lower in MTX 
monotherapy group compared to randomized groups (p=0.01).  
 
4.2.3 Radiographic progression and hand bone loss 
The sensitivity of DXR change during 1 year (cut-off > 2.5 mg/cm
2 
per month) to predict 
radiographic progression was low (26%) while the specificity was 89%. Patients with HBL 
during 1 year had significantly more radiographic progression after 2 years (Total SHS-score, 
Erosion and joint space narrowing score) compared to those without HBL. The number of 
patients with radiographic progression was 50 (14/44 in the monotherapy, 23/53 in triple 
therapy and 13/47 in MTX + INF group, respectively). When each therapy group was 
analyzed separately, only patients in triple therapy group had significant radiographic 
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progression when they had HBL. Patients with HBL had significantly greater risk of 
radiographic progression over 24 months (odds ratio 3.09, 95% CI =1.20–7.79, p =0.02). This 
was most marked and only statistically significant in the group of patients receiving triple 
therapy (odds ratio 4.15, 95% CI = 1.05–16–35, p = 0.04) and not in two other groups.  
 
4.3 Paper III 
Current smoking status is a strong predictor of radiographic progression in 
early rheumatoid arthritis: results from the SWEFOT trial 
4.3.1 Characterization of the patients: 
In this study, 311 of the 487 patients from the SWEFOT trial were included that is those with 
complete available radiographic data at the baseline and 1 year follow-up visit. Baseline 
characteristics of this sub-group did not differ from the whole SWEFOT population. Patients 
were grouped as current smokers versus non-smokers (pooling past-smoker and not-smoker). 
Radiographic progression was defined as an increase in total SHS-score of at least 5 points 
after one year, as previously described [84, 87, 146]. The proportion of patients with erosions 
at the baseline was 41% and the median (IQR) of SHS-score was 2 (0-6). 
 
4.3.2 Association between radiographic progression and baseline parameters 
Significant associations were observed between rapid radiographic progression (SHS-score > 
5 points) and smoking status, erosions at the baseline, DAS28 and its inflammatory 
components (ESR, CRP).  Table 8 demonstrates these associations. 
 
 
TABLE 8: Significant association between radiographic progression during 1 year and some 
of the baseline characteristics in paper III (for the whole model and variable list see paper III). 
*Adjusted for gender, symptom duration, current smoking, baseline erosions and HAQ  
All patients Patients in multivariate model
Unadjusted OR (95% CI) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Current smokers vs. Non-smokers 2.70 (1.50 to 4.87) 2.85 (1.57 to 5.16) 2.67 (1.44 to 4.95)
Erosions 2.38 (1.41 to 4.00) 2.43 (1.40 to 4.22) 2.28 (1.28 to 4.07)
DAS 28 (per unit increase) 1.36 (1.06 to 1.74) 1.30 (1.00 to 1.69) 1.37 (1.04 to 1.81)
CRP (<10, 10-35, >35 mg/dL) 1.66 (1.18 to 2.34) 1.68 (1.18 to 2.41) 1.52 (1.03 to 2.24)
ESR (<21, 21-50, > 50 mm/h) 1.59 (1.09 to 2.30) 1.68 (1.13 to 2.49) 1.67 (1.10 to 2.53)
* 
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Since high co-linearity was observed for HAQ and DAS28 and its components, so only HAQ 
was kept in the model, and excluded when DAS28 and its components were analyzed. 
Further adjustment for treatment strategy did not change the associations between these 
significant predictors and radiographic progression. Using a cut-off of 5 units for 
radiographic progression according to the SHS-score, no significant association was observed 
for auto-antibody status. Based on 3-dimensional matrix including the main predictors, 
current smoking status, baseline erosion and CRP in tertiles, 63% of patients who had all 3 
predictors developed radiographic progression after 1 year. This proportion for patients 
without these 3 baseline parameters was 12%.  Separate analysis for ACPA positive and 
negative patients showed the lowest proportion of patients with radiographic progression in 
ACPA negative patients lacking all baseline predictors. 
 
FIGURE 23: Risk matrix showing the proportion of SWEFOT patients in paper III who 
developed radiographic progression after 1 year. 
 
4.4 Paper IV 
Diagnostic utility of musculoskeletal ultrasound in patients with suspected 
arthritis – a probabilistic approach 
4.4.1 Characterization of the patients:  
One hundred and three patients with a mean age (SD) of 50 (16.4) years were included 
consecutively in this study between 2010 and 2013. All patients had suspected inflammatory 
arthritis but had no prior rheumatologic diagnosis. The proportion of patients with ACPA and 
RF positivity was 29% and 34%, respectively. The mean (SD) symptom duration was 8.5 
(3.8) months. 76 (73.8%) of patients were female. Figure 24 demonstrates the proportion of 
patients with different final diagnosis at the end of the follow-up time (1-4 years).  
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At the end of follow-up, 53.4% of the original cohort (55/103) had been treated with anti-
rheumatic therapy including DMARDs, corticosteroids and biologics. 35 were treated with 
MTX and 14 had other DMARDs. 18 patients were treated with biologics as a monotherapy 
or in combination with DMARDs.  
 
 
FIGURE 24: At the end of the follow up time, 65% (67/103) of patients were diagnosed as 
having any inflammatory arthritis 
 
4.4.2 The impact of MSUS in early assessment of patients with suspected 
inflammatory arthritis 
In this study 63.1% of patients had MSUS finding in B-mode and/or color Doppler 
ultrasound that indicated inflammatory arthritis. The diagnostic certainty for inflammatory 
arthritis and RA increased after performing MSUS, as shown in figure 25. McNemar 
statistical test was used to analyze changes in proportions from pre-test to post-test 
likelihood. After presentation of MSUS information to our four rheumatologists, the number 
of patients with highest and lowest diagnostic probability was increased. Parallel reduction 
was observed in proportion of patients with greatest diagnostic uncertainty.   
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FIGURE 25: The proportion of patients with maximal diagnostic certainty for inflammatory 
arthritis and RA before and after performing MSUS (p<0.001 for both IA and RA).  
 
4.4.3: The relation between MSUS findings at the first evaluation and final 
diagnosis/ongoing anti-rheumatic treatment at the end of follow-up time 
 In more than 95% of patients it was agreement between MSUS positive/negative findings 
and the final diagnosis. Similar results were obtained when accuracy of MSUS was 
investigated by the number of patients with anti-rheumatic treatment (ART) at the end of the 
follow up time. The patients were very unlikely to be prescribed ART when the pre-test and 
post-test likelihood was less than 40% (pre-test: 2/28; post-test: 0/34). However, a significant 
increase was observed in proportion of patients for whom diagnostic likelihood was more 
than 80% and treated with ART before and after MSUS (pre-test: 23/103; post-test: 48/103, 
p<0.001). 
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5 DISCUSSION 
This thesis is based on the clinical use and role of X-ray imaging and musculoskeletal 
ultrasound of the joints in diagnosis and management of inflammatory arthritis in general and 
rheumatoid arthritis specifically.  
 
5.1 Paper I 
Paper I provided new information about the clinical and structural outcomes of RA during the 
first two years of the disease course in patients who responded well to the first treatment 
already after 3-4 months. The core of this paper is that early RA patients with initial good 
response to MTX monotherapy continue to do well clinically during the first two years but 
radiographic damage is surprisingly high in certain number of these patients. One reflection 
here is whether MTX monotherapy is enough and acceptable therapy for all patients with 
early RA and one plausible explanations regarding radiographic progression in the certain 
number of these RA patients is maybe subclinical synovitis in a group of RA patients that can 
be identified by the modern imaging modalities including MRI and MSUS [147]. Based on 
the results from paper I, some clinical points can be discussed.  
- MTX has been shown to have a protective effect in terms of radiographic destruction 
[27]. Additionally the practical ease of use of MTX and lack of frequently serious 
adverse event have contributed that MTX has been dominant DMARD during the last 
20 years. Some previous studies including paper I in this thesis have demonstrated 
that MTX does not have a protective radiographic effect in all patients with good 
initial clinical response and a proportion of patients treated with MTX as a 
monotherapy have radiographic progression despite no or low disease activity [84, 98, 
148, 149].  
- MTX is still the most common used anti rheumatic drug for treatment of RA. 
Although other DMARDs and biologic agents in combination with MTX have been 
shown to be superior to MTX as a monotherapy regarding both clinical and 
radiographic outcomes, the cost and risk for adverse events of combination therapy 
should be considered. O´Dell et al showed that combination therapy with MXT, SSZ 
and HCQ was superior to MTX monotherapy in RA patients who did not responded 
to at least one DMARD [35]. It is actually reasonable to treat this group of patients 
more intensified even with combination biologics and MTX. The RA population in 
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paper I and study by O´Dell et al. are different since in the SWEFOT trial, all patients 
were treated by MTX initially and as explained in the results 147 of 487 patients 
responded well to MTX monotherapy. In COBRA trial, the patients treated with 
combination SSZ, MTX and high-dose rapidly tapered steroids had better 
radiographic outcomes than those treated with a single DMARD which was SSZ and 
not MTX [150]. MTX in combination with biologics has also been shown to be 
superior to MTX alone in early RA patients regarding radiographic progression [98, 
99]. Considering all above, the important question is whether it is necessary to treat 
all early RA patients more intensified initially or not and the answer is still “No”. The 
explanation is the cost of treatment with biologics and more importantly the side 
effect of these drugs and also the combination of DMARDs that leads to more often 
monitoring. Radiographic progression has been observed in a group of early RA 
patients with good initial clinical response. Importantly, identifying this group of RA 
patients at the time of diagnosis and/or during the first year should be considered 
more.  
- Most early RA patients who achieved low disease activity after 3-4 months of MTX 
monotherapy continued to have low disease activity during 2 years follow-up, and 
additional treatment was needed infrequently but some radiological progression 
occured in a proportion of the patients, and may be marked or severe in some, even 
despite sustained DAS28 remission. One important reflection here is whether DAS28 
remission criteria is enough for assessment of disease activity since it does not include 
evaluation of the feet and also allows for a few swollen joint which means patients in 
DAS28 remission may actually be in minimal disease activity state and not true 
remission [151]. In study I, When SDAI and CDAI criteria were used for definition of 
remission, no significant difference was observed neither for radiographic progression 
since both these index are simplifications of DAS28. Accordingly, two main points 
should already be considered at the diagnose time and during the first year of the 
disease course: 1- selecting the patients with the risk factor for poor prognosis and 
worse outcome from the beginning as will be discussed later in paper III. 2- Taking 
advantage of modern imaging modalities including DXR, MSUS or MRI more 
frequently specially during the first year of RA. Based on our experience from early 
RA screening at the Karolinska University Hospital, at the disease onset and also at 
the early stage of the disease course in a group of early RA patients, affected joint 
areas are the feet and also tendons. So the careful evaluation of RA patients with 
modern imagning modalities like MSUS should be considered more frequently since 
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the method has been shown to be superior to clinical examination to identify synovitis 
and other inflammatory conditions [92, 126].  
-  Despite a subset of patients had severe radiographic progression after 2 years there 
was no significant difference in the decrease of functional status measured by HAQ 
disability index in this group compared to non-progressors. Part of explanation here is 
that the HAQ mainly evaluates reversible disability in the short terms and irreversible 
disability in the long terms. Another explanation may be that HAQ values in our 
patient cohort were generally low and HAQ has a floor effect. Radiographic 
progression did not have signifanct influence on funtional status. Accordingly, the 
question is whether it sould be necessary to consider more intensified therpy for 
patient with radiographic progression? To be able to answer this important question, 
clinical and radiographic data from 5 and 10 years follow-up of the SWEFOT 
population are needed.  
 
Taken together, identifying the patients who need more intensified treatment in the beginning 
of the disease is certainly important. Monitoring of the disease activity during the first years 
of RA with more sensitive methods in clinical rheumatologic practice and using of potential 
clinical predictors for radiographic progression at the time of diagnosis should be considered 
more in the future.   
 
5.2 Paper II 
The main finding of study II was that HBL (DXR-BMD > 2.5 mg/cm
2 
per month) after one 
year predicted radiographic progression after 2 years in patients with early RA. The finding is 
consistent with previous studies [119-121, 152]. Since the SWEFOT trial was not designed 
for this study from the beginning, only in 159 patients the DXR analysis was performed on 
the radiographs of the hands that were correctly timed and taken with the same modality at 
the baseline and after one year. As a consequence, for some patients, the baseline and 12-
month radiographs were not taken using the same type of instrument and these images could 
not be analyzed. Based on the results from paper II, some observations could be discussed: 
- There is no consensus for definition of hand bone loss, measured by DXR technique. 
In two previous studies, the smallest detectable change in DXR-BMD was used for 
definition of HBL [119, 120] while in the study by Kaptanovic et al, the definition of 
HBL was BMD reduction more than median for the whole group of  patients and 
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those with HBL at one year had elevated Larsen score at 1 year and up to 20 years 
[121]. In the study by Hoff et al. HBL at one year predicted radiographic progression 
after 5 and 10 years. In paper II and also the study by Forslind et al. HBL at one year 
was predictor for radiographic progression after 2 years. However the cut-off for 
definition of HBL was different in these two studies. In our study, the fixed threshold 
levels, recommended by the device manufacturer (Sectra, Sweden), were used for 
analysis and HBL was defined as DXR-BMD change rate ≥ 2.5 mg/cm2/month (0.03 
g/cm
2 
per 12 months)   . This value is higher than the thresholds used in the previous 
studies. One explanation is that using the fixed threshold levels makes the findings as 
usable as possible for clinical interpretations but to be able to conclude this, it is 
necessary to use similar threshold levels in other RA populations.  
- Less HBL was observed in patients with good clinical response to initial MTX 
treatment after 3-4 months. One explanation here is the findings from the study by 
Revu et al. showing that MTX decreases synovial cellularity as well as RANK 
expression and RANKL/OPG ratio and might have a direct effect on bone 
metabolism in treatment of RA [34]. Less HBL in MTX monotherapy group in our 
study is not consistent with BeSt and PREMIER studies [124, 153]. One plausible 
explanation is that in the SWEFOT trial MTX monotherapy group had good clinical 
response to the treatment already at the 3-4 months follow-up visit. Despite less HBL 
in this group, radiographic progression was more pronounced compared to patients 
who received combination MTX + INF, showing the protective role of TNF inhibition 
regarding radiographic progression in RA patients.  
- Maybe the main important reflection from paper II and similar studies is the practical 
usefulness of the DXR technique to find the patients who are categorized as having 
higher risk for radiographic progression. In all studies the assessment of HBL has 
been done after one year. It means that the rheumatologists in the clinical praxis 
should have two radiographs of the hands (importantly taken for the aim of DXR 
analysis) with one year time interval to be able to evaluate BMD change in order to 
predict radiographic outcomes later in the disease course. This is actually not practical 
and neither reasonable since treatment of RA should be evaluated earlier as EULAR 
recommended [89]. Therefore an important question is whether DXR-BMD change 
after 3 or 6 months can provide useful information.    
Taken together, DXR-technique may have a role in predicting radiographic outcome in RA 
patients if there is a specific definition for HBL and also if future studies indicate that DXR-
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BMD change after 3-6 months provides the similar results as in the paper II and other 
referred studies.  
 
5.3 Paper III 
 As previously discussed, it is important to find RA patients who are likely to develop 
significant radiographic progression as early as possible, preferably at the time of diagnosis. 
In paper I we indicated that a proportion of early RA patients developed significant 
radiographic progression despite having no or low clinical disease activity, during the follow-
up period.  
Results from paper III indicated that smoking habits associated significantly with rapid 
radiographic progression in early RA patients, visualized by a multivariate logistic regression. 
Several studies indicated that using a risk matrix may be clinical useful to predict rapid 
radiographic progression (RRP, increase in SHS score > 5 unit after 1 year) [85-88]. Visser et 
al. showed that seropositivity, baseline CRP level and presence of erosions at the baseline 
visit were significant independent predictors for RRP in the risk matrix [88]. Risk matrix 
model, generated from ASPIRE early RA data set demonstrated that radiographic damage at 
the baseline was not among the main prognostic variable [87]. None of the previous studies 
has evaluated whether smoking habits associate with RRP. However several earlier studies 
indicated that RA patients who smoke develop more radiographic damage and also respond 
worse to ART [85-88]. Some practical conclusions could be made based on the results from 
paper III: 
- Current smoking habits should be considered as a strong independent predictor for 
radiographic progression in patients with early RA. The finding was perhaps not 
surprising since several earlier study demonstrated an association between smoking 
habits and both clinical and radiological outcomes of RA. However, smoking habits 
have not been included in any of the previously published studies on risk matrices of 
radiographic progression. 
- Based on the previously published studies about pathogenesis of RA, smoking 
induces citrullination and may be regarded as a mediator of ACPA-positivity. 
Therefor, patients in this study were stratifiaed into two aetiologically distinct 
subgroups of ACPA-positive and ACPA-negative disease. However ACPA-positivity 
can also be an outcome of smoking and thus a potential collider.  
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- The patients in this study represent an unselected early RA population. Additionally 
the management of the patients reflects common standard care [49]. The findings for 
the independent predictors remained even after adjustment for treatment strategy 
which surprisingly is not consistent with previous studies[87, 88].  
- In clinical praxis, it is maybe easier to translate the findings from paper III and prior 
similar studies into choice of treatment and management for individual patients with 
recently diagnosed RA.  
Taken together, the identified clinical predictors in this study and similar earlier studies 
are easily accessible and actually include as part of routine rheumatologic care at the time 
of diagnosis. Thus these objective clinical findings should be considered more in order to 
manage every individual RA patient.  
 
5.4 Paper IV  
Paper IV provided information about the role of diagnostic MSUS in patients with suspected 
inflammatory arthritis. The core of the paper IV is that MSUS greatly increased the 
diagnostic certainty for inflammatory arthritis in general and for RA in particular. Since 
earlier treatment of RA results in better structural and functional outcome [154, 155] there is 
a need to identify RA-patients at the early stages and with more certainty. Traditional 
evaluation of patients with suspected inflammatory arthritis used to include medical history, 
physical examination, complemented by blood test and conventional radiography. Using 
these tools, a sizeable proportion of patients with suspected inflammatory arthritis are not 
reliably diagnosed in the early stages of the disease. More recently MSUS has been shown to 
be superior to traditional methods to identify synovitis and soft tissue inflammation and 
several studies have confirmed the validity of MSUS for detecting synovitis and soft tissue 
inflammation [125, 127-130, 156-158].  
As EULAR has recommended, when there is diagnostic doubt, MSUS or MRI can be used to 
improve the diagnostic certainty of RA above clinical criteria alone [144]. This 
recommendation is based on five observational studies (2 with MSUS and 3 with MRI). One 
of these [159] showed a significant improvement in diagnostic certainty for seronegative 
arthritis, primary and inflammatory osteoarthritis but an increase in diagnostic certainty for 
RA was not statistically significant in that study as shown in table 9.  
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TABLE 9: Diagnostic certainty before and after MSUS in study by Matsos et al. 
 
Similar to this original study we aimed in paper IV to estimate the diagnostic confidence for 
inflammatory arthritis using a five-point scale before and after performing MSUS in patients 
with suspected inflammatory arthritis. The McNemar statistical test was used in both paper 
IV and the study by Matsos et al. to determine the differences in pre-test and post-test 
diagnostic likelihood. The main difference is that the increase in diagnostic certainty for RA 
(pooling seropositive and seronegative) was statistically significant in our study maybe due to 
that in the study by Matsos et al, only joints requested by the rheumatologists were scanned 
rather than a pre-specified number of joints in the hands and feet as in our study. Based on the 
results from paper IV, six interesting observations could be made which supported the utility 
of MSUS in early diagnosis of inflammatory arthritis:  
- The increase in diagnostic certainty for inflammatory arthritis in general and for RA 
in particular was highly significant supporting the first EULAR recommendation for 
the use of MSUS in management of RA.  
- MSUS reduced the number of patients in whom diagnostic uncertainty was maximal. 
Some patients moved to the higher likelihood and were diagnosed as having 
inflammatory arthritis and accordingly started treatment with ART earlier increasing 
the chance of a better outcome. Another group of patients moved to the lesser 
likelihood and referred back to the general practitioner.  
- Theoretically, increase in the diagnostic certainty might have less to do with the 
patients’ final diagnosis and more with the rheumatologists´ certainty after 
performing the test (in this study MSUS). However, the patients with inflammatory 
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arthritis in general and RA in particular as final diagnosis moved to the higher 
certainty in post-MSUS evaluation when the classical analysis was performed. For 
classical analysis, MSUS findings were divided in 4 categories as explained in paper 
IV. The categorisation was only performed in order to investigate the reliabiliy of 
MSUS evaluation performed by the ultrasound specialist and also comparison of 
MSUS finding with the final diagnosis and the number of patients with anti-rheumatic 
treatment at the end of follow up time. This observation is consistent with the 
previous study that confirmed validity of MSUS in identification of synovitis and soft 
tissue inflammation.  
- In the vast majority (>95%) of patients, there was agreement between MSUS findings 
and final diagnosis. Similar results were also obtained when MSUS findings and anti-
rheumatic treatment were compared at the end of the follow up time. Cut-off for 
MSUS positive findings was grade one for definition of positive signs in both B-mode 
and CDUS according to the scoring system by Ohrnhorf et al [160]. In 5 patients there 
was disagreement between MSUS findings and final diagnosis. Two patients with 
sign of synovitis in MSUS achieved no final diagnosis of inflammatory arthritis and 3 
patients without any sign of inflammation in MSUS were diagnosed as having UIA. 
Follow-up of these 5 patients showed that 3 patients without any MSUS sign of 
inflammation had no obvious clinical arthritis and no anti-rheumatic therapy neither at 
the last follow up visit. So MSUS findings could be trusted even more in these cases. 
The main MSUS finding in 2 patients who were referred back was sign of 
inflammation in one wrist and one of them also had increased acute phase reactant. 
Our rheumatologist’s assessment in these 2 patients disregarded these findings. 
- Increase in diagnostic certainty using MSUS was observed in both ACPA/RF positive 
and negative patients. This is not consistent with a previous study by Pratt et al. In 
that study seropositivity had an excellent discriminatory ability and addition of MSUS 
did not improve more predictive accuracy [140]. However there are some main 
structural differences between our study and that study. One key difference between 
the two studies is the number of scanned joints which was 16 in that study and at least 
26 in our study. We performed MSUS of the wrist in 3 positions as described in paper 
IV while scanning of the wrist was not performed at all in that study. Another 
difference here is that we had a prospective design and our focus was on whether 
MSUS could influence and increase the diagnostic certainty during the rheumatologic 
investigation. 
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- MSUS examination of the hands and feet was performed in the whole group 
irrespective of symptoms reported by the patients. Moreover, any symptomatic joint 
was also scanned by MSUS. It is one of the main differences between this paper and 
study by Matsos et al. As previously shown, in RA patients with asymptomatic joints 
and normal clinical examination, modern imaging technique including MSUS has 
shown subclinical synovitis in a large proportion of patients [141]. This was also the 
case in a certain number of our patients in paper IV.  
Based on these findings, routine MSUS examination of the hands and feet in patients with 
suspected inflammatory arthritis has great clinical significance at the time of diagnosis.  
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6 CONCLUSION 
 
i. RA patients with an initial good response to MTX monotherapy continue to do well 
clinically during the first two years, but the findings about structural damages in 
significant proportion of these patients suggest that MTX monotherapy might not be 
the perfect initial therapy for all early RA patients.  
 
ii. Monitoring of radiographic response in early RA patients with good clinical response 
to the fisrt DMARD therapy seems to be an important complement to the clinical 
assessment.  
 
iii. Integrating MSUS into clinical practice and possibly extended use of MRI to detect 
subclinical synovitis in early RA patients should be considered more often in the 
future. 
 
iv. DXR-technique may have a role in predicting radiographic outcome in early RA 
patients but further studies are needed.  
 
v. In RA patients, subjective and objective clinical variables (e.g. smoking status, 
erosions and acute phase reactant) at the time of diagnosis should be considered more 
in order to predict radiographic outcome and accordingly to decide the type of 
treatment. 
 
vi. In patients with suspected inflammatory arthritis, the utility of MSUS is most 
impressive when diagnostic uncertainty is maximal. Accordingly, by increasing 
diagnostic certainty patients will be prescribed anti-rheumatic therapy with more 
certainty. 
 
vii. Musculoskeletal ultrasound screening of patients with suspected inflammatory 
arthritis greatly increases the diagnostic certainty when added to routine clinical and 
laboratory examination. 
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7 FUTURE PLANS 
 
- To study 5 and 10 years clinical and radiographic outcomes of MTX responders 
patients in the SWEFOT population. Since this group of patients have been followed 
based on clinical routine, there is risk for many missing data specially radiographic 
data. Maybe one of the interesting point to be studied is changes in functional status 
measured by HAQ disability index in the group of patients with radiographic 
progression since we did not observed any signifanct difference between progressors 
and non-progressor regarding decrease in HAQ after 2 years. Another point to be 
studied may be change of ART during the time in the progressors vs. non-progressor. 
 
- To study the relationship between RA disease activity measured by Doppler 
quantification technique at the baseline and the subsequent clinical response (EULAR 
response) to anti-rheumatic treatment during 12 months. 
 
- To compare the RA disease activity measured by Doppler quantification technique 
with conventional clinical methods and semi- quantitative Doppler assessment. 
Additionally, to define different grades of semi-quantitative ultrasound Doppler score 
with doppler quantifiation technique. The interestning question here is that in 
defferent grades of semi-quantitative ultrasound Doppler score, how many Doppler 
pixels kan be indicated and if Doppler quatification technique verify semi-quantitative 
ultrasound Doppler score. 
 
- To study the clinical utility of flouresence Optical Imaging (FOI) in patients with 
early inflammatory arthritis and compare results to musculoskeletal ultrasound 
findings at the same time.  
 
- Identification of early RA patients with higher risk for radiographic progression 
according to the risk matrix model and combine the result with musculoskeletal 
ultrasound finding at the time of diagnosis. The main question here is whether the 
grade of inflammation measured by Doppler ultrasound, together with other clinical 
variables can predict radiographic progression in the risk matrix (Ongoing collecting 
of data in the NORD-STAR trial). 
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- To determine how different degrees of disease activity, measured by ultrasound semi-
quantitative score in B-mode and CDUS, at baseline and at 12 weeks follow-up 
correlate with clinical response and radiographic progression at 6 or 12 months in 
patients with early RA who receive 4 different anti rheumatic treatments: MTX in 
combinaton with 1- SSZ and GCs with tapering; 2- Certolizumab; 3- Abatacept; 4- 
Tocilizumab (Ongoing collecting of data in the NORD-STAR trial). 
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